Is Rapamycin Dead? — A Conversation with Matt Kaeberlein

Can we actually slow biological aging? In Episode 34 of Decoding Longevity, Raghav Sehgal and Dr. Macsue Jacques are joined by Professor Matt Kaeberlein for a wide-ranging conversation about aging biology, rapamycin, and the future of longevity science. Matt explains how research on mTOR helped shape our understanding of aging and why rapamycin remains one of the most debated interventions in the field. He also discusses what human trials can—and cannot—tell us so far. The conversation then moves beyond rapamycin, covering Aura Biomedical and AI-powered lifespan research, the Dog Aging Project and TRIAD trial, companion animal longevity, and the growing role of science in longevity biotech and investment. A conversation about one of the biggest questions in geroscience: How close are we to actually changing the way organisms age? 🎙️ Hosted by: Dr. Raghav Sehgal Dr. Macsue Jacques